Niagen

RCT supports nicotinamide riboside boost for muscle mitochondrial biogenesis

19-Jan-2023 By Stephen Daniells

Supplementation with nicotinamide riboside may improve muscle mitochondrial biogenesis, according to data from a first-of-its kind five-month-long clinical study with twins.

ChromaDex keeps foot on sales & research pedal even as stubborn losses persist

13-May-2022 By Hank Schultz

Branded ingredient supplier ChromaDex announced an 18% sales gain in a recent earrings report. A continued push to increase the science behind its TruNiagen brand is part of the reason, the company’s co-founder said.

NutraWomen Wednesday: Yasmeen Nkrumah-Elie, PhD, Global Director of External Research, ChromaDex

06-Apr-2022 By Danielle Masterson

Yasmeen Nkrumah-Elie, PhD, oversees external Research, managing a portfolio of over 200 studies, as well as supporting marketing, regulatory, and scientific affairs projects. The Global Director of External Research for ChromaDex has over 13 years of...

ChromaDex passes research program milestone with 100th Niagen study

02-Feb-2022 By Hank Schultz

ChromaDex has announced the publication of the 100th study under a research program centered on its Niagen ingredient.

In communicating research results, ChromaDex runs afoul of COVID-19 watchdogs

07-Dec-2020 By Hank Schultz

The US Food and Drug Administration has issued an additional raft of warning letters on COVID-19 claims. One major industry name — ChromaDex — appeared on the list.

Humanitarian grant awarded for study on the impact of NAD booster supplements on lactation, brain development in rodents

11-Oct-2019 By Danielle Masterson

NAD has become highly regarded in scientific research in recent years because of its role in biological functions. Now, Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, will receive a humanitarian grant...

Tru Niagen expands international footprint with expansion to Canada

18-Dec-2018 By Adi Menayang

Healthy aging supplement Tru Niagen, owned by California-based ChromaDex, has been approved for sale in Canada by the country’s health authority Health Canada.

Jaksch says move into chairman role part of ChromaDex's pivot toward finished goods

14-May-2018 By Hank Schultz

A strategic pivot toward finished products underpins his impending move toward an advisory role, said ChromaDex CEO Frank Jaksch.

ChromaDex posts sales rise amid continued losses, sluggish stock price

20-Mar-2017 By Hank Schultz

ChromaDex has reported a rapid rise in sales driven mainly by its Niagen ingredient. But the company continues to post losses, and the stock price has failed to recover from a steep slide more than nine months ago.

Drug development, continued R&D to carry ChromaDex through soft earnings patch, exec says

29-Nov-2016 By Hank Schultz

Fluctuating sales have pushed ChromaDex Corp. back into the red after a brief flurry operating at a break-even point. CEO Frank Jaksch said the company is on track despite the renewed losses and depressed stock price.

ChromaDex closes deal to place Niagen in wide array of national chains

28-Jan-2016 By Hank Schultz

ChromaDex has hit another milestone in the market penetration of its Niagen ingredient with a deal that will put it into a number of national retail chains.

ChromaDex files successful NDI on Niagen; surging sales of ingredient helps firm near break-even mark

17-Nov-2015 By Hank Schultz

ChromaDex has announced a successful New Dietary Ingredient notification on its Niagen ingredient. Strong demand for the ingredient has driven the company to a sixth consecutive quarter of record earnings and has helped ChromaDex near break-even territory...

News in brief

Chromadex reports 97% increase in ingredient sales

09-May-2014 By Stephen DANIELLS

The success and demand for Chromadex’s Niagen-branded nicotinamide riboside ingredient are driving ingredient sales for the Californian company, with more research to be published expected to further boost the ingredient.